Feb 25, 2014 - news
MedTest, a leading global clinical diagnostics company, is very pleased to announce the appointment of Jenna Edgar to the position of Quality Assurance Laboratory Supervisor. Ms. Edgar has served for the past year and a half as a Laboratory Technician. Her promotion is in recognition of her exceptional performance and leadership skills.
In her capacity as QA Laboratory Supervisor, Jenna will oversee daily laboratory operations and personnel, and lead the team in workflow related to product release and stability testing. "Under Jenna’s leadership, I am confident the QA Laboratory Team will play a major role in meeting MedTest's Quality Assurance needs and requirements, and achieving our growth objectives," said Ron Jamison, Vice President of Technical Operations with MedTest.
Jenna holds a Bachelors of Science Degree and has been an ASCP registered Clinical Laboratory Scientist for over 5 years.
Jan 2, 2014 - press releases
Mindray™ BS-200, Poly-Chem® 180, and Open Channel Applications
Canton, Michigan, January 2, 2014 – MedTest DX, A MedTest Company, is pleased to announce the introduction of a broad, highly complex drug of abuse menu for the Mindray™ BS-200 Chemistry Analyzer, the Poly-Chem® 180 Analyzer and as open channel applications on other clinical chemistry analyzers such as the Beckman Coulter AU instrument series in the United States. The introduction of this menu enables MedTest DX to provide high quality drug of abuse reagents to customers focused on pain management and drug abuse testing.
Mindray™ BS-200 and Open Channel Applications
MedTest DX introduces 16 highly complex, urine drugs of abuse tests that include:
6-Acetylmorphine, Amphetamine, Barbiturate, Benzodiazepine, Buprenorphine (Suboxone), Cannabinoid (THC), Cocaine Metabolite, Ecstasy (MDMA), Ethanol, Methadone, Methadone Metabolite (EDDP), Methamphetamine, Opiates, Oxycodone, Phencyclidine and Propoxyphene
MedTest DX introduces 5 highly complex, urine drugs of abuse tests (6-Acetylmorphine, Buprenorphine, Oxycodone, Phencyclidine and Propoxyphene) to its existing 10 tests that make up the moderately complex test menu.
“Menu expansion enables MedTest DX to meet our customer’s needs in the pain management and drug abuse testing arena” said Hanjoon Ryu, CEO of MedTest. “Our drugs of abuse offering on analyzers like the Mindray™ BS-200 enable our pain management clinic customers to implement a quality urine screening process while allowing our laboratory customers to minimize their overall cost and enhance their overall efficiency.”
Jul 22, 2013 - press releases
(Canton, Michigan & Mahwah, New Jersey) Today, Mindray and MedTest jointly announced a US exclusive partnership that will greatly expand collaboration between the two organizations. Covering the chemistry and drugs of abuse (DoA) market segments, the agreement spans the BS-200 Clinical Analyzer, the world's leading bench-top chemistry analyzer, Pointe Scientific's reagents exclusively manufactured and FDA cleared for the BS-200 analyzer, and MedTest DX's sales, customer service and support.
The partnership enables US laboratory customers to purchase the analyzer, reagents, and service from one company, MedTest. MedTest will be the exclusive US distributor of the BS-200 analyzer and it's consumables for the chemistry and moderately complex DoA markets. MedTest will also market the BS200 analyzer for the highly complex DoA market on a non-exclusive basis. MedTest is committed to providing existing and new customers with enhanced customer support and differentiated products.
Hanjoon Ryu, CEO of MedTest, stated: "US physician office laboratories and small hospital and commercial labs deserve a more integrated service provider who offers innovative instruments and quality reagents. We are delighted to announce this strategic partnership and to ensure that the partnership brings substantial improvement in serving our customers. "
Finn Li, PhD, Sales Manager of Mindray IVD, stated: "We are excited to forge this US exclusive partnership with MedTest. As Mindray has grown rapidly in global markets, this partnership will make it possible for Mindray to further enhance its presence in the US in-vitro diagnostic market and further introduce a series of new and innovative products for the clinical laboratory."
About MedTest: MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing. In June, MedTest acquired Pointe Scientific, a company that has been developing , manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981.
About Mindray: Mindray is a leading developer , manufacturer and marketer of medical devices worldwide. Mindray maintains the global headquarters in Shenzhen, China, the U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From the main manufacturing and engineering base in China, Mindray supplies through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems.
For additional information, please contact:
|Finn Li, PhD||Debbie Whitehair, MT(ASCP)SC|
|IVD Sales Manager||Vice President, Marketing|
|905-886-0589, Ext. 2158||484-748-1603|
Jul 19, 2013 - press releases
Canton, Michigan – July 19, 2013 Pointe Scientific, A MedTest Company, is pleased to announce the availability of an automated Hemoglobin A1c assay for the Beckman Coulter™ DxC 600 analyzer. This assay provides the laboratory with on-board cell lysing, thus eliminating off-line dilutions, which impact technologist’s time and overall laboratory workflow.
Performance comparison to the manufacturer’s product yielded excellent correlation and precision data.
“We are pleased to be able to offer this automated solution for the DxC 600 analyzer” said Hanjoon Ryu, CEO of MedTest. “Current available assays for this analyte require off-line manual steps which impacts a laboratory’s overall efficiency goal.”
For more information on the Hemoglobin A1c automated assay for the Beckman Coulter™ DxC 600 analyzer, please call us at 800.445.9853 or visit www.pointescientific.com.
Jun 3, 2013 - press releases
Cortlandt Manor, New York – June 3, 2013 MedTest Holdings, the parent company of MedTest DX, Inc. (“MedTest”) has signed a definitive agreement to acquire Pointe Scientific, Inc. (“Pointe”) located in Canton, Michigan. Financial details of the acquisition were not disclosed. MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing.
Pointe has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981. Pointe’s robust R&D program focuses on continual improvement of existing products and bringing new products and technologies to the marketplace.
“We are thrilled to add the Pointe Scientific team to our family” said Hanjoon Ryu, CEO of MedTest. “Combined, MedTest and Pointe become uniquely positioned to offer a broad range of clinical chemistry products and services for clinical laboratories and physician office laboratories worldwide. Going forward, we will continue to serve our customers with the same commitment to quality and customer service that both companies have proven in the past.”
Together, Pointe and MedTest offer a broad reagent and instrument product portfolio including testing solutions for drugs of abuse, general chemistry, immunochemistry, diabetes and cardiovascular diseases serving physician’s office laboratories, reference laboratories, hospital laboratories and commercial laboratories.